Direct isolation of recombinant human antibodies against group B Neisseria meningitidis from scFv expression libraries

Journal of Immunological Methods

Volumn 283, Issue 1-2, 2003, Pages 247-259

  Stacy, John Erik ^a   Kausmally, Louise ^a   Simonsen, Bjørg ^a   Nordgard, Silje H ^a   Alsøe, Lene ^a   Michaelsen, Terje E ^b,c   Brekke, Ole Henrik ^a,d  

^a Affitech AS   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d NONE   (Norway)

Author keywords

Group B Neisseria meningitidis; Human antibodies; scFv

Indexed keywords

BACTERIAL VACCINE; DNA; RECOMBINANT ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY ISOLATION; ANTIBODY SCREENING; ANTIGEN BINDING; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; CROSS REACTION; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENETIC VARIABILITY; HUMAN; LYMPHOCYTE; MEMBRANE VESICLE; MOLECULAR CLONING; NEISSERIA MENINGITIDIS; NORMAL HUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURFACE PLASMON RESONANCE; VACCINATION;

ESCHERICHIA COLI; NEISSERIA; NEISSERIA MENINGITIDIS;

EID: 0344628556     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2003.09.015     Document Type: Article

References (33)

1. Aase A., Høiby E.A., Michaelsen T.E. Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine. Scand. J. Immunol. 47:1998;388.
2. Baines P.B., Hart C.A. Severe meningococcal disease in childhood. Br. J. Anaesth. 90:2003;72.
3. Berger M., Shankar V., Vafai A. Therapeutic applications of monoclonal antibodies. Am. J. Med. Sci. 324:2002;14.
4. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., Holten E., Lindbak A.K., Nokleby H., Rosenqvist E.et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 338:1991;1093.
5. Brekke O.H., Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev., Drug Discov. 2:2003;52.
6. Boyum A. Separation of leukocytes from blood and bone marrow. Introduction. Scand. J. Clin. Lab. Invest., Suppl. 97:1968;7.
7. Burnie J., Matthews R., Carter T., Beaulieu E., Donohoe M., Chapman C., Williamson P., Hodgetts S. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect. Immun. 68:2000;3200.
8. Burnie J., Carter T., Rigg G., Hodgetts S., Donohoe M., Matthews R. Identification of ABC transporters in vanomycin-resistant Enterococcus faecium as potential targets for antibody therapy. FEMS Immunol. Med. Microbiol. 33:2002;179.
9. Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. 8:2002;833.
10. Casadevall A. Antibodies for defense against biological attack. Nat. Biotechnol. 20:2002;114.
11. Casal J., Aguilar L., Jado I., Yuste J., Giménez M.J., Prieto J., Fenoll A. Effects of Specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of β-lactams in a mouse sepsis model. Antimicrob. Agents Chemother. 46:2002;1340.
12. de Wildt R.M.T., Mundy C.R., Gorick B.D., Tomlinson I.M. Antibody arrays for high-throughput screening of antibody-antigen interactions. Nat. Biotechnol. 18:2000;989.
13. Derkx B., Wittes J., McCloseky R. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. Clin. Infect. Dis. 28:1999;770.
14. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 13:1983;355.
15. Frank D.W., Vallis A., Wiener-Kronish J.P., Roy-Burman A., Spack E.G., Mullaney B.P., Megdoud M., Marks J.D., Fritz R., Sawa T. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J. Infect. Dis. 186:2002;64.
16. Fredriksen J.H., Rosenqvist E., Wedege E., Bryn K., Bjune G., Froholm L.O., Lindbak A.K., Mogster B., Namork E., Rye U.et al. Production, characterization and control of MenB vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Annals. 14:1991;67.
17. Hackett S.J., Thomson A.P.J., Hart C.A. Cytokines, chemokines and other molecules involved in meningococcal disease. J. Med. Microbiol. 50:2001;847.
18. Ihle O., Beckstrøm K.J., Michaelsen T.E. Cloning, sequencing and expression of immunoglobulin variable regions of murine monoclonal antibodies specific for the P1.7 and P1.16 PorA protein loops of Neisseria meningitidis. Scand. J. Immunol. 57:2003;453.
19. Kipriyanov S.M., Kuprianova O.A., Little M., Moldenhauer G. Rapid detection of antibody fragments against cell-surface antigens by flow cytometry. J. Immunol. Methods. 196:1996;41.
20. Knappik A., Ge L., Honegger A., Pack P., Fischer M., Wellnhofer G., Hoess A., Wolle J., Pluckthun A., Virnekas B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296:2000;57.
21. Martin D.R., Walker S.J., Baker M.G., Lennon D.R. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J. Infect. Dis. 177:1998;497.
22. Munro R. Meningococcal disease: treatable but still terrifying Intern. Med. J. 32:2002;165.
23. Næss L.M., Aarvak T., Aase A., Oftung F., Høiby E.A., Sandin R.H., Michaelsen T.E. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunisation with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine. 17:1999;754.
24. Næss L.M., Torill T., Kristoffersen A.-C., Aaberge I.S., Høiby E.A., Rosenqvist E. Immunogenicity of a combination of two different outer membrane protein based meningococcal group B vaccines. Caugant D.A., Wedege E. Abstracts: 13th International Pathogenic Neisseria Conference, Oslo, Nordberg Aksidenstrykkeri AS, Oslo. 2002;284.
25. Norderhaug L., Olafsen T., Michaelsen T.E., Sandlie I. Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J. Immunol. Methods. 204:1997;77.
26. Oostenbrink R., Oostenbrink J.B., Moons K.G., Derksen-Lubsen G., Essink-Bot M.L., Grobbee D.E., Redekop W.K., Moll H.A. Cost-utility analysis of patient care in children with meningeal signs. Int. J. Technol. Assess. Health Care. 18:2002;485.
27. Sblattero D., Bradbury A. A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology. 3:1998;271.
28. Scheld W.M., Koedel U., Nathan B., Pfister H.W. Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J. Infect. Dis. (Suppl. 2):2002;S225.
29. Skerra A., Dreher M.L., Winter G. Filter screening of antibody Fab fragments secreted from individual bacterial colonies: specific detection of antigen binding with a two-membrane system. Anal. Biochem. 196:1991;151.
30. Stephens D.S., Zimmer S.M. Pathogenesis, therapy and prevention of meningococcal sepsis. Curr. Infect. Dis. Rep. 4:2002;377.
31. van Deuren M., Brandtzaeg P., van der Meer J.W.M. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin. Microbiol. Rev. 13:2000;144.
32. Wildes S.S., Tunkel A.R. Meningococcal vaccines: a progress report. BioDrugs. 16:2002;321.
33. Wyle F.E., Artenstein M.S., Brandt B.L., Tramont E.C., Kasper D.L., Altieri P.L.S., Berman L., Lowenthal J.P. Immunological response in man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126:1972;514.